Cannabis Sales Projected to Increase as California Paves the way for Recreational use

Friday, January 19, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

NEW YORK, January 19, 2018 /PRNewswire/ --

According to a report

by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is forecast to grow at a CAGR of 21.1% between 2017 to 2024 or culminating to $63.5 billion by
2024. The market is going through a period of strong growth thanks to increasing legalization and decriminalization of cannabis products across North America and Europe. The report indicates that due to the complex regulatory structure at state and federal level, the full potential of the market is not yet clear. A recent report published by Arcview Market Research explains that growth of the legal cannabis industry will reaccelerate beginning 2018, as adult use sales ramp up in Canada, California, and Massachusetts along with medical sales in Florida. Sugarmade, Inc. (OTC: SGMD), Lexaria Bioscience Corp. (OTC: LXRP), GB Sciences, Inc. (OTC: GBLX), mCig, Inc. (OTC: MCIG), Terra Tech Corp. (OTC: TRTC)

In states like California for example, where new recreational cannabis laws went into effect on January 1st, 2018, analysts are projecting an increase in sales of Cannabis. The new industry is also expected to contribute to California's tax revenue. The LA times reported that, California is on the verge of creating a legal market for marijuana worth more than $5 billion that will help make the state a destination for pot-loving tourists.

Sugarmade, Inc. (OTC: SGMD) announced yesterday that the, legalization of recreational cannabis within the state of California is already having a positive impact on the businesses of Sugarmade and BizRight Hydroponics, Inc. The two companies are currently in process of implementing a master marketing agreement, creating one of the largest publically traded cannabis and hydroponics supply companies. While the California market, considering its strong economic clout is certainly important, many other states are also now beginning to issue cultivation licenses, adding additional fuel to the already growing cultivation supply market.

Mr. Jimmy Chan, CEO of Sugarmade, commented, "2018 will certainly be very busy for our Company. We could not be more pleased with the growth we are seeing from almost all geographic areas, but California is clearly developing into a marketplace that is exceeding even our very positive previous expectations."

In California, a cultivator must first obtain a local cultivation license before applying for a state license. Through January 13, 2018, the California Department of Food & Agriculture had issued only 442 temporary cannabis cultivation licenses; however, there are thousands of applications still pending at the city and country level. Thus, the number of state issued licenses is expected to grow dramatically over the coming months.

Mr. Chan continued, "We are especially excited about the increase in business being seen from California commercial growers as both local and state licenses are now being issued. We are already seeing an increase in demand even though only 442 licenses have been issued thus far by regulators, but there are thousands of additional licenses still pending. Nearly all of these cultivators will need supplies and as one of the largest suppliers with product lines for both indoor and outdoor cultivation, we think we are very well positioned to realize further acceleration in demand. Thus, we are in process of revising our internal revenue estimates for 2018 and beyond. We expect to provide formal guidance over the coming weeks."

While the California market is very exciting, there many other cultivation markets expected to come online during 2018. States such as Florida, Texas, Arkansas, New Mexico, Alaska, Vermont and Pennsylvania, among others, are also experiencing a cultivation license backlog.

Sugarmade is currently expanding its staffing, especially related to finance and accounting, in order to prepare for the significant increase in business the companies are expecting. BizRight produced in excess of $30 million in revenues during 2017, with substantial growth expected for 2018. Sugarmade expects to provide detailed revenue guidance to its investors over the coming weeks, but is preliminarily expecting revenue for 2018 to top $40 million."

Lexaria Bioscience Corp. (OTCQX: LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. On December 13, 2017, the company announced the United States Patent and Trademark Office has granted patent number 9,839,612 B2 for the use of DehydraTECHTM technology as a delivery platform for a wide variety of Active Pharmaceutical Ingredients including all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications; and nicotine. In one aspect a method of treating a condition is provided wherein a cannabinoid is used to treat conditions selected from the group consisting of cardiac diseases such as heart disease, ischemic infarcts, and cardiometabolic disorders, neurological diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia, and Human Immunodeficiency Virus (HIV) dementia; obesity; metabolic disorders such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer chemotherapy, benign prostatic hypertrophy; irritable bowel syndrome, biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine or cocaine addiction.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. On December 13, 2017, the company announced its development of a cannabis strain that has an extremely high THC concentration, and also has a specifically-defined terpene profile, meaning that this potent strain may have significant medical benefits. This strain is the result of an ongoing research project and is one of many tangible results of the coordination of the three operating units--- Life Sciences, Tissue Propagation, and Cultivation Labs.  GB Sciences is a fully integrated cannabis company with three complementary operating units. The internal pipeline is now fully solidified; the Life Sciences division researches and develops the profile for a strain that is thought to be medicinally important; the Tissue Propagation team acquires the specified genetics and begins the propagation process to provide clean, healthy, starter plants so that verifiable and consistent results can be gained;  the new plants then move into the Cultivation Labs precision controlled growing environment and are matured under stringently monitored growing conditions.

mCig, Inc. (OTCQB: MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. On January 02, 2018, the company announced that its Grow Contractors (GC) division has secured cannabis cultivation and manufacturing licenses for one of its clients in San Gabriel Valley, California. The licenses permit the production and sale of cannabis products throughout California, a state with a new recreational marijuana economy said to be valued at $7 billion and currently takes 30% market share of the US cannabis market.

Terra Tech Corp. (OTCQX: TRTC) is a vertically integrated cannabis-focused agriculture company. On January 1, 2018, the company announced that it has received State of California Temporary Authorization to distribute and retail cannabis, and expects to receive authorizations to cultivate and manufacture cannabis for California's adult-use and medical markets, effective January 1, 2018. Terra Tech plans to commence adult-use cannabis sales to the California market immediately through its Blümretail dispensaries located in Oakland and Santa Ana. Terra Tech first started selling medical cannabis products to patients in California through its Blüm dispensary in Oakland. In anticipation of adult-use sales, the Company opened a second Blüm retail location in Santa Ana, California in September, 2017 and is currently constructing a Blüm dispensary in San Leandro, which is expected to open to the public in early 2018. The Company is also expanding its cultivation facilities through its 'Craft Cultivation' model, and has signed two craft cultivators, based in Honeydew and Salinas, to ramp production of the Company's brand of premium cannabis. The Company's IVXX cannabis is grown and harvested under the safest and most beneficial conditions, free of toxic pesticides, harmful molds and chemical residues. All products are rigorously tested and certified to the highest standards of potency and purity.

Subscribe Now! Watch us report from LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Sugarmade Inc. financial news dissemination and PR services, has been compensated four thousand dollars by meridian ventures. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further information:  +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store